Loading…

Progressive neuronal activation accompanies epileptogenesis caused by hippocampal glutamine synthetase inhibition

Loss of glutamine synthetase (GS) in hippocampal astrocytes has been implicated in the causation of human mesial temporal lobe epilepsy (MTLE). However, the mechanism by which the deficiency in GS leads to epilepsy is incompletely understood. Here we ask how hippocampal GS inhibition affects seizure...

Full description

Saved in:
Bibliographic Details
Published in:Experimental neurology 2017-02, Vol.288, p.122-133
Main Authors: Albright, Benjamin, Dhaher, Roni, Wang, Helen, Harb, Roa, Lee, Tih-Shih W., Zaveri, Hitten, Eid, Tore
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c475t-5f53f5e7b78a3e217ee62c9eff961c28e400fceee72e5110fc4a592852241d753
cites cdi_FETCH-LOGICAL-c475t-5f53f5e7b78a3e217ee62c9eff961c28e400fceee72e5110fc4a592852241d753
container_end_page 133
container_issue
container_start_page 122
container_title Experimental neurology
container_volume 288
creator Albright, Benjamin
Dhaher, Roni
Wang, Helen
Harb, Roa
Lee, Tih-Shih W.
Zaveri, Hitten
Eid, Tore
description Loss of glutamine synthetase (GS) in hippocampal astrocytes has been implicated in the causation of human mesial temporal lobe epilepsy (MTLE). However, the mechanism by which the deficiency in GS leads to epilepsy is incompletely understood. Here we ask how hippocampal GS inhibition affects seizure phenotype and neuronal activation during epilepsy development (epileptogenesis). Epileptogenesis was induced by infusing the irreversible GS blocker methionine sulfoximine (MSO) unilaterally into the hippocampal formation of rats. We then used continuous video-intracranial electroencephalogram (EEG) monitoring and c-Fos immunohistochemistry to determine the type of seizures and spatial distribution of neuronal activation early (1–5days postinfusion) and late (16–43days postinfusion) in epileptogenesis. Early in epileptogenesis, seizures were preferentially mild (stage 1–2), activating neurons in the entorhinal-hippocampal area, the basolateral amygdala, the piriform cortex, the midline thalamus, and the anterior olfactory area. Late in epileptogenesis, the seizures were generally more severe (stages 4–5) with neuronal activation extending to the neocortex, the bed nucleus of the stria terminalis, the mediodorsal thalamu\s, and the central nucleus of the amygdala. Our findings demonstrate that inhibition of GS focally in the hippocampal formation triggers a process of epileptogenesis characterized by gradual worsening of seizure severity and involvement of progressively larger neuronal populations over a period of several weeks. Knowledge about the underlying mechanism of epileptogenesis is important because such knowledge may result in more specific and efficacious treatments of MTLE by moving away from large and poorly specific surgical resections to highly targeted surgical or pharmacological interventions of the epileptogenic process. •Inhibition of glutamine synthetase in the hippocampal formation leads to epilepsy.•The epileptic seizures involve a small number of brain areas initially.•The seizures are mostly low grade (not severe) during the early phase.•The seizures progressively worsen over the next several weeks.•The worsening is accompanied by seizure involvement of multiple brain areas.
doi_str_mv 10.1016/j.expneurol.2016.10.007
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5547560</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014488616303272</els_id><sourcerecordid>1835528359</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-5f53f5e7b78a3e217ee62c9eff961c28e400fceee72e5110fc4a592852241d753</originalsourceid><addsrcrecordid>eNqFkU2P0zAQhi0EYrsLfwF85JJiO3GcXJBWKz5WWgkOcLZcZ9JO5dhZ26nov8elSwUnLvZo5p13RvMQ8pazNWe8fb9fw8_ZwxKDW4uSKNk1Y-oZWXHWs0o0NXtOVozxpmq6rr0i1yntGWN9I9RLciWUanvF1Yo8fothGyElPAD9beiNo8ZmPJiMwZfQhmk2HiFRmNHBnMMWPCRM1JolwUA3R7rDeQ7WFKGjW7dkM6EHmo4-7yCbBBT9Djd4cnxFXozGJXj99N-QH58-fr_7Uj18_Xx_d_tQ2UbJXMlR1qMEtVGdqUFwBdAK28M49i23ooOGsdECgBIgOS9xY2QvOilEwwcl6xvy4ew7L5sJBgs-R-P0HHEy8aiDQf1vxeNOb8NBS1kWaFkxePdkEMPjAinrCZMF54yHsCTNu1pKUZ6-SNVZamNIKcJ4GcOZPgHTe30Bpk_AToUCrHS--XvLS98fQkVwexZAudUBIepkEbyFASPYrIeA_x3yCx-jsVg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835528359</pqid></control><display><type>article</type><title>Progressive neuronal activation accompanies epileptogenesis caused by hippocampal glutamine synthetase inhibition</title><source>ScienceDirect Journals</source><creator>Albright, Benjamin ; Dhaher, Roni ; Wang, Helen ; Harb, Roa ; Lee, Tih-Shih W. ; Zaveri, Hitten ; Eid, Tore</creator><creatorcontrib>Albright, Benjamin ; Dhaher, Roni ; Wang, Helen ; Harb, Roa ; Lee, Tih-Shih W. ; Zaveri, Hitten ; Eid, Tore</creatorcontrib><description>Loss of glutamine synthetase (GS) in hippocampal astrocytes has been implicated in the causation of human mesial temporal lobe epilepsy (MTLE). However, the mechanism by which the deficiency in GS leads to epilepsy is incompletely understood. Here we ask how hippocampal GS inhibition affects seizure phenotype and neuronal activation during epilepsy development (epileptogenesis). Epileptogenesis was induced by infusing the irreversible GS blocker methionine sulfoximine (MSO) unilaterally into the hippocampal formation of rats. We then used continuous video-intracranial electroencephalogram (EEG) monitoring and c-Fos immunohistochemistry to determine the type of seizures and spatial distribution of neuronal activation early (1–5days postinfusion) and late (16–43days postinfusion) in epileptogenesis. Early in epileptogenesis, seizures were preferentially mild (stage 1–2), activating neurons in the entorhinal-hippocampal area, the basolateral amygdala, the piriform cortex, the midline thalamus, and the anterior olfactory area. Late in epileptogenesis, the seizures were generally more severe (stages 4–5) with neuronal activation extending to the neocortex, the bed nucleus of the stria terminalis, the mediodorsal thalamu\s, and the central nucleus of the amygdala. Our findings demonstrate that inhibition of GS focally in the hippocampal formation triggers a process of epileptogenesis characterized by gradual worsening of seizure severity and involvement of progressively larger neuronal populations over a period of several weeks. Knowledge about the underlying mechanism of epileptogenesis is important because such knowledge may result in more specific and efficacious treatments of MTLE by moving away from large and poorly specific surgical resections to highly targeted surgical or pharmacological interventions of the epileptogenic process. •Inhibition of glutamine synthetase in the hippocampal formation leads to epilepsy.•The epileptic seizures involve a small number of brain areas initially.•The seizures are mostly low grade (not severe) during the early phase.•The seizures progressively worsen over the next several weeks.•The worsening is accompanied by seizure involvement of multiple brain areas.</description><identifier>ISSN: 0014-4886</identifier><identifier>EISSN: 1090-2430</identifier><identifier>DOI: 10.1016/j.expneurol.2016.10.007</identifier><identifier>PMID: 27769717</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; c-Fos ; Disease Models, Animal ; Electroencephalography ; Entorhinal cortex ; Enzyme Inhibitors - toxicity ; Epilepsy - chemically induced ; Epileptogenesis ; Glutamate-Ammonia Ligase - metabolism ; Hippocampus ; Hippocampus - cytology ; Hippocampus - drug effects ; Hippocampus - physiology ; Limbic structures ; Male ; Methionine Sulfoximine - toxicity ; Muscarinic Agonists - toxicity ; Neurons - drug effects ; Neurons - pathology ; Pilocarpine - toxicity ; Rats ; Rats, Sprague-Dawley</subject><ispartof>Experimental neurology, 2017-02, Vol.288, p.122-133</ispartof><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-5f53f5e7b78a3e217ee62c9eff961c28e400fceee72e5110fc4a592852241d753</citedby><cites>FETCH-LOGICAL-c475t-5f53f5e7b78a3e217ee62c9eff961c28e400fceee72e5110fc4a592852241d753</cites><orcidid>0000-0001-9217-6393 ; 0000-0001-5296-9575</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27769717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Albright, Benjamin</creatorcontrib><creatorcontrib>Dhaher, Roni</creatorcontrib><creatorcontrib>Wang, Helen</creatorcontrib><creatorcontrib>Harb, Roa</creatorcontrib><creatorcontrib>Lee, Tih-Shih W.</creatorcontrib><creatorcontrib>Zaveri, Hitten</creatorcontrib><creatorcontrib>Eid, Tore</creatorcontrib><title>Progressive neuronal activation accompanies epileptogenesis caused by hippocampal glutamine synthetase inhibition</title><title>Experimental neurology</title><addtitle>Exp Neurol</addtitle><description>Loss of glutamine synthetase (GS) in hippocampal astrocytes has been implicated in the causation of human mesial temporal lobe epilepsy (MTLE). However, the mechanism by which the deficiency in GS leads to epilepsy is incompletely understood. Here we ask how hippocampal GS inhibition affects seizure phenotype and neuronal activation during epilepsy development (epileptogenesis). Epileptogenesis was induced by infusing the irreversible GS blocker methionine sulfoximine (MSO) unilaterally into the hippocampal formation of rats. We then used continuous video-intracranial electroencephalogram (EEG) monitoring and c-Fos immunohistochemistry to determine the type of seizures and spatial distribution of neuronal activation early (1–5days postinfusion) and late (16–43days postinfusion) in epileptogenesis. Early in epileptogenesis, seizures were preferentially mild (stage 1–2), activating neurons in the entorhinal-hippocampal area, the basolateral amygdala, the piriform cortex, the midline thalamus, and the anterior olfactory area. Late in epileptogenesis, the seizures were generally more severe (stages 4–5) with neuronal activation extending to the neocortex, the bed nucleus of the stria terminalis, the mediodorsal thalamu\s, and the central nucleus of the amygdala. Our findings demonstrate that inhibition of GS focally in the hippocampal formation triggers a process of epileptogenesis characterized by gradual worsening of seizure severity and involvement of progressively larger neuronal populations over a period of several weeks. Knowledge about the underlying mechanism of epileptogenesis is important because such knowledge may result in more specific and efficacious treatments of MTLE by moving away from large and poorly specific surgical resections to highly targeted surgical or pharmacological interventions of the epileptogenic process. •Inhibition of glutamine synthetase in the hippocampal formation leads to epilepsy.•The epileptic seizures involve a small number of brain areas initially.•The seizures are mostly low grade (not severe) during the early phase.•The seizures progressively worsen over the next several weeks.•The worsening is accompanied by seizure involvement of multiple brain areas.</description><subject>Animals</subject><subject>c-Fos</subject><subject>Disease Models, Animal</subject><subject>Electroencephalography</subject><subject>Entorhinal cortex</subject><subject>Enzyme Inhibitors - toxicity</subject><subject>Epilepsy - chemically induced</subject><subject>Epileptogenesis</subject><subject>Glutamate-Ammonia Ligase - metabolism</subject><subject>Hippocampus</subject><subject>Hippocampus - cytology</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - physiology</subject><subject>Limbic structures</subject><subject>Male</subject><subject>Methionine Sulfoximine - toxicity</subject><subject>Muscarinic Agonists - toxicity</subject><subject>Neurons - drug effects</subject><subject>Neurons - pathology</subject><subject>Pilocarpine - toxicity</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><issn>0014-4886</issn><issn>1090-2430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqFkU2P0zAQhi0EYrsLfwF85JJiO3GcXJBWKz5WWgkOcLZcZ9JO5dhZ26nov8elSwUnLvZo5p13RvMQ8pazNWe8fb9fw8_ZwxKDW4uSKNk1Y-oZWXHWs0o0NXtOVozxpmq6rr0i1yntGWN9I9RLciWUanvF1Yo8fothGyElPAD9beiNo8ZmPJiMwZfQhmk2HiFRmNHBnMMWPCRM1JolwUA3R7rDeQ7WFKGjW7dkM6EHmo4-7yCbBBT9Djd4cnxFXozGJXj99N-QH58-fr_7Uj18_Xx_d_tQ2UbJXMlR1qMEtVGdqUFwBdAK28M49i23ooOGsdECgBIgOS9xY2QvOilEwwcl6xvy4ew7L5sJBgs-R-P0HHEy8aiDQf1vxeNOb8NBS1kWaFkxePdkEMPjAinrCZMF54yHsCTNu1pKUZ6-SNVZamNIKcJ4GcOZPgHTe30Bpk_AToUCrHS--XvLS98fQkVwexZAudUBIepkEbyFASPYrIeA_x3yCx-jsVg</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Albright, Benjamin</creator><creator>Dhaher, Roni</creator><creator>Wang, Helen</creator><creator>Harb, Roa</creator><creator>Lee, Tih-Shih W.</creator><creator>Zaveri, Hitten</creator><creator>Eid, Tore</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9217-6393</orcidid><orcidid>https://orcid.org/0000-0001-5296-9575</orcidid></search><sort><creationdate>20170201</creationdate><title>Progressive neuronal activation accompanies epileptogenesis caused by hippocampal glutamine synthetase inhibition</title><author>Albright, Benjamin ; Dhaher, Roni ; Wang, Helen ; Harb, Roa ; Lee, Tih-Shih W. ; Zaveri, Hitten ; Eid, Tore</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-5f53f5e7b78a3e217ee62c9eff961c28e400fceee72e5110fc4a592852241d753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>c-Fos</topic><topic>Disease Models, Animal</topic><topic>Electroencephalography</topic><topic>Entorhinal cortex</topic><topic>Enzyme Inhibitors - toxicity</topic><topic>Epilepsy - chemically induced</topic><topic>Epileptogenesis</topic><topic>Glutamate-Ammonia Ligase - metabolism</topic><topic>Hippocampus</topic><topic>Hippocampus - cytology</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - physiology</topic><topic>Limbic structures</topic><topic>Male</topic><topic>Methionine Sulfoximine - toxicity</topic><topic>Muscarinic Agonists - toxicity</topic><topic>Neurons - drug effects</topic><topic>Neurons - pathology</topic><topic>Pilocarpine - toxicity</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Albright, Benjamin</creatorcontrib><creatorcontrib>Dhaher, Roni</creatorcontrib><creatorcontrib>Wang, Helen</creatorcontrib><creatorcontrib>Harb, Roa</creatorcontrib><creatorcontrib>Lee, Tih-Shih W.</creatorcontrib><creatorcontrib>Zaveri, Hitten</creatorcontrib><creatorcontrib>Eid, Tore</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Albright, Benjamin</au><au>Dhaher, Roni</au><au>Wang, Helen</au><au>Harb, Roa</au><au>Lee, Tih-Shih W.</au><au>Zaveri, Hitten</au><au>Eid, Tore</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progressive neuronal activation accompanies epileptogenesis caused by hippocampal glutamine synthetase inhibition</atitle><jtitle>Experimental neurology</jtitle><addtitle>Exp Neurol</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>288</volume><spage>122</spage><epage>133</epage><pages>122-133</pages><issn>0014-4886</issn><eissn>1090-2430</eissn><abstract>Loss of glutamine synthetase (GS) in hippocampal astrocytes has been implicated in the causation of human mesial temporal lobe epilepsy (MTLE). However, the mechanism by which the deficiency in GS leads to epilepsy is incompletely understood. Here we ask how hippocampal GS inhibition affects seizure phenotype and neuronal activation during epilepsy development (epileptogenesis). Epileptogenesis was induced by infusing the irreversible GS blocker methionine sulfoximine (MSO) unilaterally into the hippocampal formation of rats. We then used continuous video-intracranial electroencephalogram (EEG) monitoring and c-Fos immunohistochemistry to determine the type of seizures and spatial distribution of neuronal activation early (1–5days postinfusion) and late (16–43days postinfusion) in epileptogenesis. Early in epileptogenesis, seizures were preferentially mild (stage 1–2), activating neurons in the entorhinal-hippocampal area, the basolateral amygdala, the piriform cortex, the midline thalamus, and the anterior olfactory area. Late in epileptogenesis, the seizures were generally more severe (stages 4–5) with neuronal activation extending to the neocortex, the bed nucleus of the stria terminalis, the mediodorsal thalamu\s, and the central nucleus of the amygdala. Our findings demonstrate that inhibition of GS focally in the hippocampal formation triggers a process of epileptogenesis characterized by gradual worsening of seizure severity and involvement of progressively larger neuronal populations over a period of several weeks. Knowledge about the underlying mechanism of epileptogenesis is important because such knowledge may result in more specific and efficacious treatments of MTLE by moving away from large and poorly specific surgical resections to highly targeted surgical or pharmacological interventions of the epileptogenic process. •Inhibition of glutamine synthetase in the hippocampal formation leads to epilepsy.•The epileptic seizures involve a small number of brain areas initially.•The seizures are mostly low grade (not severe) during the early phase.•The seizures progressively worsen over the next several weeks.•The worsening is accompanied by seizure involvement of multiple brain areas.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27769717</pmid><doi>10.1016/j.expneurol.2016.10.007</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-9217-6393</orcidid><orcidid>https://orcid.org/0000-0001-5296-9575</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0014-4886
ispartof Experimental neurology, 2017-02, Vol.288, p.122-133
issn 0014-4886
1090-2430
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5547560
source ScienceDirect Journals
subjects Animals
c-Fos
Disease Models, Animal
Electroencephalography
Entorhinal cortex
Enzyme Inhibitors - toxicity
Epilepsy - chemically induced
Epileptogenesis
Glutamate-Ammonia Ligase - metabolism
Hippocampus
Hippocampus - cytology
Hippocampus - drug effects
Hippocampus - physiology
Limbic structures
Male
Methionine Sulfoximine - toxicity
Muscarinic Agonists - toxicity
Neurons - drug effects
Neurons - pathology
Pilocarpine - toxicity
Rats
Rats, Sprague-Dawley
title Progressive neuronal activation accompanies epileptogenesis caused by hippocampal glutamine synthetase inhibition
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A06%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progressive%20neuronal%20activation%20accompanies%20epileptogenesis%20caused%20by%20hippocampal%20glutamine%20synthetase%20inhibition&rft.jtitle=Experimental%20neurology&rft.au=Albright,%20Benjamin&rft.date=2017-02-01&rft.volume=288&rft.spage=122&rft.epage=133&rft.pages=122-133&rft.issn=0014-4886&rft.eissn=1090-2430&rft_id=info:doi/10.1016/j.expneurol.2016.10.007&rft_dat=%3Cproquest_pubme%3E1835528359%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-5f53f5e7b78a3e217ee62c9eff961c28e400fceee72e5110fc4a592852241d753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1835528359&rft_id=info:pmid/27769717&rfr_iscdi=true